The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.

Adherent stromal cells cultured under three dimensional conditions are provided, characterized, and distinguished from adherent stromal cells cultured under two dimensional conditions.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy and a method of treatment to facilitate same. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes and the identification of therapeutic targets. Taught herein is a composition comprising reagents required for prognostic evaluation and treatment.

Described are devices, compounds and methods for detecting an analyte in a sample. More particularly this disclosure provides SPR and LSPR sensors modified by NTA linkers for binding a ligand and/or analyte. The NTA linkers of the disclosure typically include a head (or anchoring site) for coupling to a surface of the SPR or LSPR sensor, a spacer, and one or more attachment sites on a distal end or ends of the spacer which couple to a ligand. The head may include a thiol for coupling the linker to a surface of the SPR or LSPR sensor. The spacer may be a carbon chain. PAG or PEG chain, or matrix material. The one or more attachment sites may be a nitrilotriacetic acid (NTA) moiety capable of chelating a transition metal ion and binding the ligand.

Disclosed is a method for evaluating the ability of a chemical substance or a chemical composition to prevent muscle fatigue and damage induced by physical exertion in humans; edible composition including at least one salt of a multivalent metal cation, at least one compound selected between vitamin E or vitamin E acetate, at least one edible polyphenol compound selected from compounds of the flavonol family, compounds of the anthocyanin family, compounds of the phenolic acid family and compounds of the flavonol family and/or the glucosylated derivatives thereof, in which the molar ratio/is of at least 0.50 and not more than 2.00; its use as a food supplement or for preparing a food supplement composition or as a drug for preventing muscle fatigue and/or muscle damage induced by physical exertion, in a method for the treatment of the human body by therapy.

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IL-6, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a cardiac Troponin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IL-6 and a second biomarker being a cardiac Troponin or Creatinine or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

A method for predicting sepsis or diagnosing systemic inflammatory response syndrome (SIRS) and/or sepsis in a subject comprises determining levels of at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine in a sample taken from the subject. The combined levels of the at least three markers are used to predict or diagnose SIRS and/or sepsis. The methods may be performed on a subject with SIRS and which is used to identify an infection in the subject. A preferred panel of markers includes CCL23, A1AT, sICAM, sICAM/VCAM-1 and CRP. Corresponding products, methods of treatment and medical uses are provided.

Compositions and methods are provided for modifying diagnosing and treating inflammatory disease. The methods and compositions can be used to ameliorate the effects of a deficiency in the LAP pathway for clearing dead cells. Thus, methods are further provided for modulating dead cell clearance using an effective amount of a pharmaceutical composition that targets the LAP pathway. Accordingly, pharmaceutical compositions that target the LAP pathway re provided herein. The methods and compositions described herein can be used to treat inflammatory disease, such as systemic lupus erythematosus (SLE).